Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COXFA4 | O00483 | 1/20 | 0.66 |
| ▸ | TLR3 | O15455 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315467 | 0.82 | COXFA4 (0.46) | COXFA4TLR3NPC1RAB9ATDP1 | |
| SCHEMBL13071290 | 0.82 | COXFA4 (0.46) | COXFA4TLR3NPC1RAB9ATDP1 | |
| SCHEMBL14139261 | 0.82 | COXFA4 (0.81) | COXFA4HIF1AEPAS1EP300 | |
| SCHEMBL14098881 | 0.80 | COXFA4 (0.74) | COXFA4HIF1AEPAS1EP300 | |
| SCHEMBL14139185 | 0.80 | COXFA4 (1.00) | COXFA4HIF1AEPAS1 | |
| SCHEMBL12315602 | 0.80 | COXFA4 (0.84) | COXFA4HIF1AEPAS1EP300 | |
| SCHEMBL12315466 | 0.79 | COXFA4 (0.46) | COXFA4TDP1HIF1AEPAS1ALDH1A1 | |
| SCHEMBL14098877 | 0.76 | COXFA4 (0.89) | COXFA4HIF1AEPAS1 | |
| SCHEMBL27665986 | 0.76 | COXFA4 (0.57) | COXFA4TLR3TDP1HIF1AEPAS1 | |
| SCHEMBL11398330 | 0.76 | COXFA4 (0.62) | COXFA4NPC1RAB9ATDP1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | COXFA4 2119/4885TLR3 3578/4885NPC1 350/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | COXFA4 2119/4885TLR3 3578/4885NPC1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.